27 results about "Inhibitory molecules" patented technology

The invention relates to application of mitogen-activated protein kinase PiPmk1 in screening molecules for inhibiting formation of a phytophthora infestans infection structure. The invention finds that the molecular marker plays a key role in the development of a phytophthora infestans cyst bud tube and / or the formation of an infection structure, which indicates that the molecular marker has the potential of serving as a target for inhibiting phytophthora infestans infection, and a corresponding molecular screening method and a generative prediction model are further developed and utilized; rapid and accurate prediction and screening of phytophthora infestans infection inhibitory molecules are realized, the research and development period and cost are greatly shortened, and a new thought and a new method are provided for development of accurate targeted green pesticides.

Compositions and methods for treating diseases associated with expression of a cancer associated antigen are disclosed. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, SHP inhibitory molecules, vectors encoding the same, and recombinant immune effector cells comprising the CARs and SHP inhibitory molecules. Methods of administering a genetically modified immune effector cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen and a SHP inhibitory polypeptide are also disclosed.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS. HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

A combination therapy comprising a semaphorin-4D inhibitory molecule and Flt3 ligand or a FLT3 agonist with or without a checkpoint inhibitor for treating cancer is disclosed.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The application relates to a novel triarylamine compound with two carbazole units introduced on a biphenyl-triarylamine and application thereof, wherein, by fixing one of the carbazole units at the ortho position of the biphenyl in the triarylamine, a twisted structure is formed, thus effectively inhibiting the aggregation of the molecule, so that a stable dense film is formed; by changing the position of the other carbazole and the structure of the other two aryl groups of the triarylamine, the energy level barrier and the hole mobility can be effectively regulated, and the efficiency and the service life of the device are improved. Meanwhile, the double-carbazole system can more effectively inhibit the diffusion of electrons from the light-emitting layer to the hole side, so that the service life of the device is further improved.

The present invention improves an effect of killing or an effect of inhibiting the growth of cancer cells. The present invention comprises: a binding domain that includes a first antigen-binding site that binds to a cancer cell and a second antigen-binding site that binds to a T cell; a cleavable sequence that is linked to the binding domain; and a masking moiety that is linked to the N-terminus of a single-chain antibody via the cleavable sequence when the binding domain is composed of the single-chain antibody, and that is linked to the C-terminus of each light chain via the cleavable sequence when the binding domain is composed of heavy chains and light chains. In a state in which the cleavable sequence is cleaved, the masking moiety functions as an agonist of a co-stimulatory molecule for the T cell or an antagonist of a co-inhibitory molecule for the T cell.

The present disclosure relates to a cell-based assay for determining in vitro tumor killing activity of immune cells expressing a chimeric antigen. The present disclosure provides an in vitro method for determining the potency (e.g., cytotoxicity) of immune cells expressing a chimeric antigen receptor (CAR) molecule. In a test sample, the CAR-expressing immune cells are incubated with target cells that express an antigen that interacts with the CAR. In a control sample, the CAR-expressing immune cells are incubated with the target cells and an inhibitory molecule that prevents the interaction between the CAR and the target cells. The amount of target cell death is determined in both the test sample and the control sample and compared.

The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The present invention relates to lipid-based nanoparticles comprising an antigen-binding domain capable of specifically binding to a target expressed on the surface of activated immune cells, and one or more mRNA molecules encoding an inhibitory protein of the activated immune cells, and to the use thereof.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

To provide an NK inhibitory molecule that can significantly suppress the killing action of NK cells in the subject's body, thereby reducing the risk of HvGD, compared to conventional genetically modified immune cells, and to provide a genetically modified immune cell that expresses the molecule.SOLUTION: Provided is an NK inhibitory molecule comprising one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, the NK inhibitory ligand specifically binding to an NK inhibitory receptor and inhibiting NK cells from killing genetically modified immune cells that express the NK inhibitory molecule. Provided is a genetically modified immune cell that expresses an NK inhibitory molecule of the invention, the expression of at least one MHC-associated gene being inhibited or silenced. Provided is use of the genetically modified immune cells in the treatment of cancer, infectious disease or autoimmune disease.SELECTED DRAWING: Figure 1

The disclosure relates to methods for treating cognitive decline or selecting subjects for treatment with an anti-semaphorin-4D antibody using the subject's Mini-Mental State Exam (MMSE) score and / or an equivalent cognitive assessment test score as a patient biomarker.

This invention belongs to the field of biomedicine and discloses the application of palmitoyltransferase ZDHHC21 in the preparation of drugs for treating breast cancer. This invention demonstrates that ZDHHC21 knockdown upregulates RIPK1 expression, which is related to signal feedback induced by CD82 palmitoylation deficiency. Depalmitoylated CD82 competitively binds to RIPK1 inhibitory molecules, thereby releasing the regulation of RIPK1, promoting the interaction and phosphorylation activation of RIPK1 and RIPK3, and subsequently upregulating MLKL expression and inducing its activation. Downstream activation of Caspase-3 ultimately initiates necroptosis. A specific regulatory axis of "ZDHHC21–CD82–pan-apoptosis" is established. This provides a potential novel therapeutic target for triple-negative breast cancer and offers a theoretical and experimental basis for therapeutic strategies targeting tumor cell death. Further research can explore the role of this regulatory axis in vivo, providing support for clinical translation.

This invention discloses a near-infrared II photothermal therapeutic agent, its preparation method, and its application, belonging to the field of optical diagnostics and treatment technology. To address the problems of insufficient light absorption, fluorescence quenching, and inadequate molecular structure optimization in existing photothermal therapeutic agents, this invention proposes a molecular design strategy of "central plane + peripheral twisting," developing a novel NIR-II photothermal therapeutic agent, 4TPE-TB, which is a near-infrared II photothermal therapeutic agent. This invention enhances the light absorption capacity of the near-infrared II photothermal therapeutic agent by strengthening the conjugation of the molecular core, and utilizes the peripheral twisted structure to suppress intermolecular stacking, significantly improving photothermal conversion efficiency and fluorescence performance, thereby achieving a comprehensive improvement in the therapeutic agent's performance.

The application discloses a kind of drug composition containing antibody drug conjugate and application thereof.The application provides a kind of drug composition 1, it includes compound C, histidine buffer, saccharide stabilizer, surfactant and water, the pH of the described drug composition 1 is 6.0-6.5;Wherein, the compound C is A-(B) n The drug composition of the application can be long-term stably stored in liquid form without freeze-drying, can effectively inhibit the aggregation and degradation of ADC molecules, has excellent biological activity and safety, greatly improves the convenience of clinical application while reducing the production cost.Meanwhile, the drug composition of the application can also maintain good stability after freeze-drying treatment and reconstitution, providing more options for clinical application.

This invention provides an antibody or antigen fragment thereof that targets human-derived CD7 and its use. CD7-CARs based on this antibody and antibody fragment have very high affinity for the CD7 antigen molecule, and inhibitory molecules containing this antibody can almost completely inhibit the expression of the CD7 molecule on the cell surface without affecting the normal amplification of T cells, thus effectively avoiding sibling killing of CD7-CAR-T cells. CD7-CAR-T cells constructed using a single-domain antibody that targets human-derived CD7 have a high killing effect on target cells.

The present application relates to a composition containing growth hormone fusion protein and its use. The composition comprises: growth hormone fusion protein, and at least one of buffer and protective agent; the use of the above composition in the preparation of a medicament for treating and / or preventing diseases related to growth hormone abnormalities. The composition of the present application can reduce or inhibit the generation of molecular fragments, improve the stability of growth hormone fusion protein during preparation and storage; and the composition does not require complex preparation process, can be directly prepared into injection with high stability, and has good long-acting pharmacokinetic characteristics.

An immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain, and a costimulatory domain and not comprising a primary signaling domain wherein the immunosuppressive protein is selected from two or more of NKG2A, TIM3, LAG3, TIGIT, CTLA4, PD1, and FasL. Engineered cells expressing the immunosuppressive molecules and compositions comprising the engineered cells. Methods of reducing immunological rejection using the immunosuppressive molecules.

The application discloses an assembly synergistic near-infrared two-region nanoparticle based on an electron-rich polymer and a preparation method and application thereof, and belongs to the technical field of precise optical diagnosis and treatment of major diseases such as tumors, and proposes an assembly synergistic strategy, takes an electron-rich block polymer as a carrier, forms an intermolecular electron donor-electron acceptor unit between the carrier and a near-infrared two-region molecule, reduces the singlet and triplet energy level difference of the molecule, promotes inter-gap crossing, effectively inhibits molecular vibration, and thus improves the diagnosis and treatment performance. Compared with a traditional performance optimization method at the molecular level, the application adopts a simple and easy self-assembly strategy, successfully overcomes the problems of low active oxygen yield and low fluorescence quantum yield of the near-infrared two-region optical diagnosis and treatment material, can provide a new and effective means for the precise diagnosis and treatment of major diseases such as tumors, and has a wide application prospect.

The present invention relates to an inhibitor of heat shock protein 90. Disclosed are a heat shock protein 90-based bivalent inhibitor, and a preparation method therefor and the use thereof. The bivalent inhibitor is a compound having a structural formula as shown in formula I: A-L-B Formula I, or a pharmaceutically acceptable salt, solvate, or optical isomer thereof, wherein A and B are ATP inhibitors of heat shock protein 90, and the motif structure of L is a flexible linker group of PEG or alkanes, or a rigid linker group comprising aryl, heteroalkyl, or heteroaryl. The bivalent inhibitor can effectively inhibit the activity of molecular chaperone HSP90, hinder the folding and modification of a substrate protein, degrade the substrate protein via a ubiquitin-proteasome degradation pathway, induce non-native dimerization of HSP90, and interfere with protein-protein interactions associated with HSP90. In addition, the bivalent inhibitor reduces the heat shock response induced by HSP90 inhibition, and exhibits potent activity in degrading the substrate protein.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The present disclosure relates to cell-based assays for determining in vitro tumor killing activity of immune cells expressing chimeric antigens. The present disclosure provides an in vitro method for determining the potency (e.g., cytotoxicity) of an immune cell expressing a chimeric antigen receptor (CAR) molecule. In a test sample, immune cells that express the CAR are incubated with target cells that express antigens that interact with the CAR. In a control sample, an immune cell expressing the CAR is incubated with a target cell and an inhibitory molecule that prevents interaction between the CAR and the target cell. The amount of target cell death in both the test sample and the control sample is determined and compared.

The invention discloses a near-infrared two-region aggregation-induced emission material, a preparation method thereof and application of the near-infrared two-region aggregation-induced emission material in brain glioma imaging. According to the structure of the near-infrared two-region aggregation-induced emission material, thiazaphthalene tetracarboxylic diimide is adopted as an electron acceptor group, triphenylamine and a methylated derivative thereof are adopted as electron donor units, and the thiazaphthalene tetracarboxylic diimide and the triphenylamine are coupled to construct an organic near-infrared two-region molecule with an intramolecular charge transfer characteristic. A methyl steric hindrance group is introduced into a limited space of an electron donor group, so that the repulsive force effect in molecules is improved, the movement of excited-state molecules is effectively inhibited, and the luminous efficiency of the molecules is remarkably improved. Meanwhile, the steric hindrance group can inhibit pi-pi interaction among molecules, and the luminous efficiency of the aggregation state is improved. The nanoparticles prepared from the aggregation-induced emission material are modified by adopting brain-targeted peptide Angiopep-2, so that accurate detection and high-contrast fluorescence imaging of mouse in-situ glioma are realized.